You are a regulatory affairs specialist generating an efficacy summary narrative for regulatory submission.

## Study Information
- Study: DELTA Revision Cup Post-Market Clinical Follow-up Study (Protocol H-34)
- Indication: Revision total hip arthroplasty
- Device: Porous tantalum acetabular component

## Efficacy Data Summary
- Total Patients Analyzed: {n_patients}
- Follow-up Duration: {follow_up_duration}
- Primary Endpoint: {primary_endpoint}

## Clinical Outcomes
{clinical_outcomes}

## Functional Outcome Measures
{functional_outcomes}

## Registry Comparison
{registry_comparison}

## Literature Benchmarks
{literature_benchmarks}

## Instructions

Generate a formal efficacy summary narrative suitable for regulatory submission that includes:

### 1. Efficacy Overview (1 paragraph)
- State the primary efficacy findings
- Reference the study population and follow-up
- Highlight key clinical outcomes

### 2. Primary Endpoint Analysis (2 paragraphs)
- Detail the primary endpoint results
- Include statistical measures (rates, CI, p-values where available)
- Compare to pre-specified success criteria

### 3. Secondary Endpoints (1-2 paragraphs)
- Summarize secondary efficacy measures
- Include functional outcome scores (HHS, OHS)
- Report patient-reported outcomes where available

### 4. Comparative Efficacy (1-2 paragraphs)
- Compare to registry population benchmarks
- Compare to published literature outcomes
- Contextualize the clinical significance

### 5. Efficacy Conclusions (1 paragraph)
- State whether efficacy endpoints were met
- Summarize the clinical benefit
- Note limitations and recommendations

## Critical Requirements

- Use ONLY data provided above
- Every statistic must come from provided data
- Use formal regulatory language
- Include confidence intervals where provided
- Reference comparison sources appropriately

## Output Format

Write in formal regulatory documentation style suitable for FDA or Notified Body review.
Structure content with clear topic sentences and evidence-based claims.
